Drug Trial Radar · NCT04718896
A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Apr 6, 2021
Primary completion
Mar 12, 2025
Study completion Mar 12, 2025
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
Conditions
- Moderate to Severe Plaque Psoriasis
Interventions
bimekizumabDrug
Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Concentration of Bimekizumab at Week 0Time frame: Baseline (Week 0)
- Plasma Concentration of Bimekizumab at Week 1Time frame: Week 1
- Plasma Concentration of Bimekizumab at Week 4Time frame: Week 4
- Plasma Concentration of Bimekizumab at Week 8Time frame: Week 8
- Plasma Concentration of Bimekizumab at Week 12Time frame: Week 12
- Plasma Concentration of Bimekizumab at Week 16Time frame: Week 16
- Plasma Concentration of Bimekizumab at Week 20Time frame: Week 20
- Plasma Concentration of Bimekizumab at Week 40Time frame: Week 40
- Plasma Concentration of Bimekizumab at Week 64Time frame: Week 64
- Plasma Concentration of Bimekizumab at Week 88Time frame: Week 88
- Plasma Concentration of Bimekizumab at Week 112Time frame: Week 112
- Plasma Concentration of Bimekizumab at Week 124Time frame: Week 124
- Plasma Concentration of Bimekizumab at Safety Follow up (SFU)Time frame: Week 140 (SFU)
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Ps0020 50344
Indianapolis, Indiana
Ps0020 50359
Cypress, Texas
Ps0020 50354
Calgary, Canada
Ps0020 50357
St. John's, Canada
Ps0020 40645
Frankfurt, Germany
Ps0020 40626
Bialystok, Poland
Ps0020 40625
Lodz, Poland
Ps0020 40396
Rzeszów, Poland
Ps0020 40335
Warsaw, Poland
Ps0020 40333
Wroclaw, Poland
Ps0020 40334
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.